BeOne Medicines (BEIGF) Total Current Liabilities (2015 - 2026)

BeOne Medicines (BEIGF) has reported Total Current Liabilities for 12 consecutive years, with $2.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 4.1% year-over-year to $2.1 billion in Q2 2026; TTM through Jun 2026 was $2.1 billion, a 4.1% decrease from a year earlier, with the FY2025 full-year figure at $1.8 billion, down 17.43% from the prior year.
• Total Current Liabilities was $2.1 billion for Q2 2026 at BeOne Medicines, up from $1.8 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $2.4 billion in Q3 2025 and troughed at $1.3 billion in Q1 2023.
• A 5-year average of $1.8 billion and a median of $1.8 billion in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 57.82% in 2024 and fell 17.43% in 2025, its largest moves.
• Over 5 years, Total Current Liabilities stood at $1.5 billion in 2022, then advanced by 23.26% to $1.8 billion in 2023, then gained by 22.36% to $2.2 billion in 2024, then slipped by 17.43% to $1.8 billion in 2025, then rose by 15.88% to $2.1 billion in 2026.
• The last three Total Current Liabilities figures came in at $2.1 billion (Q2 2026), $1.8 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.